$ANGO

Nighan Warren JR sold $344K of ANGO

Nighan Warren JR (SVP Quality and Regulatory) sold 23,370 shares of ANGIODYNAMICS INC (ANGO) at $14.72 ($0.34M total) on 2026-07-30.

Original reporting
SEC EDGAR · Nighan Warren JR
Published Jul 31, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ANGO
Neutral
high confidence
Mentioned
$ANGO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANGONeutralLow
01

Why it matters

This provides transparency on insider selling activity but does not introduce new operational or financial information about ANGO.

02

Market read

Traders may note insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not state motivations, and the absence of a disclosed 10b5-1 plan does not prove non-routine intent.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-31 after-hours; sale dated 2026-07-30

Background

The article is a SEC Form 4 insider transaction disclosure for ANGIODYNAMICS (ANGO).

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

Form 4 shows ANGIODYNAMICS SVP Quality and Regulatory Nighan Warren Jr sold 23,370 shares at $14.72 on 2026-07-30.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is a disclosed insider transaction, but it does not include new company performance, guidance, or regulatory/contract developments.

Market effects

Minimal; this is company-specific insider dealing with no sector-wide regulatory or demand signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the market may over-interpret the signal.

Key entities

  • ANGIODYNAMICS INC

    US-listed company subject of the Form 4 insider sale disclosure.

  • Nighan Warren Jr

    SVP Quality and Regulatory who sold shares via open-market sale.

Related articles

$ANGOMed

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.